Axe Compute Reports $12 Million in Executed Agreements Providing $835 Thousand in Estimated Monthly Income Entering Q2 2026
April 3, 2026
April 3, 2026
April 3, 2026
April 3, 2026
April 2, 2026
Patrick Gruber, CEO of Gevo (NASDAQ: GEVO), shares how the company is pioneering renewable, drop-in hydrocarbon jet fuels that are cost-competitive with traditional petroleum-based alternatives. With over 450 patents and projects backed by a $1.63B DOE loan guarantee, Gevo is scaling commercial production through facilities in South Dakota and North Dakota. The company’s ethanol-based jet fuel, carbon capture, and RNG assets are unlocking significant revenue streams—positioning Gevo to become EBITDA positive in 2025. With $270M+ in cash, strategic partnerships, and bipartisan support for 45Z tax credits, Gevo is accelerating the transition to net-zero aviation fuels.
May 22, 2025Study will highlight novel iNKT cell-based combinations in checkpoint-refractory disease Data expected to inform immune modulation, treatment sequencing strategy, and clinical durability of response NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and […]
April 3, 2026
Notifications have no immediate effect on the listing or trading of the Company’s securities on Nasdaq Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirements The Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder value […]
April 3, 2026
SUNNYVALE, Calif., April 02, 2026 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported submission to United States Food and Drug Administration (FDA) of the CardiAMP HF clinical study data and on its plans to meet with the FDA to […]
April 2, 2026
KUALA LUMPUR, Malaysia, April 01, 2026 (GLOBE NEWSWIRE) — Treasure Global Inc. (NASDAQ: TGL) (“Treasure Global” or the “Company”), a Southeast Asia–anchored technology company, today announced that its subsidiary, Tadaa Technologies Sdn Bhd has signed a strategic Memorandum of Understanding (MOU) with Anhui Fuyuan Electromechanical Technology Co. Ltd., establishing a framework to explore expansion into […]
April 1, 2026
April 3, 2026
April 3, 2026
April 3, 2026
April 3, 2026
April 3, 2026
April 2, 2026
April 2, 2026
April 2, 2026